Browse the latest research summaries in the field of pain management for spinal cord injury patients and caregivers.
Showing 541-550 of 682 results
The Journal of Spinal Cord Medicine, 2018 • January 1, 2018
This letter to the editor discusses the feasibility of remotely supervised tDCS for neuropathic pain in a person with spinal cord injury. The study involved training the participant and their caretake...
KEY FINDING: Remotely supervised tDCS is feasible for individuals with SCI and neuropathic pain.
Journal of Pain Research, 2018 • January 1, 2018
This study investigates factors influencing placebo responses in SCI patients with neuropathic pain using individual patient data from six RCTs. The analysis revealed that sex and baseline pain intens...
KEY FINDING: Larger placebo responses were observed in male subjects with SCI-related neuropathic pain.
JOURNAL OF NEUROTRAUMA, 2018 • November 1, 2018
The study investigated the relationship between plasma GFAPab, CRMP2ab, and neuropathic pain in SCI patients. The presence of plasma GFAPab in the chronic stage of injury does not differentiate betwee...
KEY FINDING: Plasma GFAPab in the chronic stage of SCI does not correlate with neuropathic pain.
Toxins, 2018 • June 1, 2018
This review examines the mechanism of central neuropathic pain and assesses the effect of BTX on central neuropathic pain. The review summarizes the mechanism of central neuropathic pain and botulinum...
KEY FINDING: BTX inhibits the secretion of substance P and CGRP from dorsal root ganglion (DRG) neurons, reduces the expression of TRPV1 and P2X3 receptors, and induces a central effect through retrograde axonal transport, all of which contribute to its potential analgesic effects.
Journal of Pain Research, 2018 • May 17, 2018
This study introduces an ovine model of neuropathic pain that allows for the investigation of spinal cord stimulation (SCS) mechanisms through behavioral and electrophysiological measures. The model i...
KEY FINDING: Peroneal nerve constriction in sheep produces a reproducible large animal model of persistent neuropathic pain.
Molecular Pain, 2018 • June 8, 2018
This study investigates the therapeutic potential of Pak1 inhibition for pain associated with cutaneous burn injury using romidepsin, an FDA-approved inhibitor. The findings demonstrate that Pak1 inhi...
KEY FINDING: Inhibition of Pak1 by romidepsin decreased dendritic spine dysgenesis in the dorsal horn of mice with burn injury.
Aust Occup Ther J, 2018 • October 1, 2018
The study examined the measurement properties of the BPI interference scale for measuring pain interference in persons with SCI. Rasch analysis was used to evaluate the dimensionality of the BPI inter...
KEY FINDING: Four of the original seven BPI interference items provide acceptable measurements of pain interference in the SCI population.
Qual Life Res, 2018 • November 1, 2018
This study compares Ecological Momentary Assessment (EMA) and End-of-Day (EOD) diaries for measuring pain intensity and pain interference in individuals with spinal cord injury (SCI). The results indi...
KEY FINDING: Five days of EOD assessments are needed for excellent reliability in measuring pain intensity, while three days are sufficient for pain interference.
Medicine, 2018 • August 3, 2018
This pilot study retrospectively investigated the feasible effect and safety of neuromuscular electrical stimulation (NMES) for the management of neuropathic pain (NPP) caused by spinal cord injury (S...
KEY FINDING: NMES did not reduce pain intensity of NPP, measured by the NRS, compared with cases in the control group.
Spinal Cord Series and Cases, 2018 • May 13, 2018
This perspective argues against the use of opioids for chronic pain after spinal cord injury (SCI), highlighting the lack of evidence for their effectiveness and the significant risks associated with ...
KEY FINDING: There is a lack of evidence supporting the long-term effectiveness of opioids for treating pain after SCI, except for one small study supporting the effectiveness of tramadol in the short term.